235 related articles for article (PubMed ID: 34427588)
1. JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy.
McGraw JM; Thelen F; Hampton EN; Bruno NE; Young TS; Havran WL; Witherden DA
J Exp Med; 2021 Oct; 218(10):. PubMed ID: 34427588
[TBL] [Abstract][Full Text] [Related]
2. The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gammadelta T cell activation.
Witherden DA; Verdino P; Rieder SE; Garijo O; Mills RE; Teyton L; Fischer WH; Wilson IA; Havran WL
Science; 2010 Sep; 329(5996):1205-10. PubMed ID: 20813954
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
4. JAML immunotherapy targets recently activated tumor-infiltrating CD8
Eschweiler S; Wang A; Ramírez-Suástegui C; von Witzleben A; Li Y; Chee SJ; Simon H; Mondal M; Ellis M; Thomas GJ; Chandra V; Ottensmeier CH; Vijayanand P
Cell Rep; 2023 Feb; 42(2):112040. PubMed ID: 36701231
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment.
Cheng S; Li M; Li C; Dai Y; Zhuo J; Wang J; Qian J; Hao Z
In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):382-396. PubMed ID: 38625487
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
9. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
10. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
13. The junctional adhesion molecule-like protein (JAML) is important for the inflammatory response during contact hypersensitivity.
Mraz V; Lohmann RKD; Menzel M; Hawkes A; Vaher H; Funch AB; Jee MH; Gadsbøll AØ; Weber JF; Yeung K; Ødum N; Woetmann A; McKay D; Witherden D; Geisler C; Bonefeld CM
Contact Dermatitis; 2023 Nov; 89(5):323-334. PubMed ID: 37619972
[TBL] [Abstract][Full Text] [Related]
14. Conditional Deletion of
Raghavan S; Tovbis-Shifrin N; Kochel C; Sawant A; Mello M; Sathe M; Blumenschein W; Muise ES; Chackerian A; Pinheiro EM; Rosahl TW; Luche H; de Waal Malefyt R
Front Immunol; 2021; 12():752348. PubMed ID: 34912335
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into γδ T cell costimulation by an anti-JAML antibody.
Verdino P; Witherden DA; Ferguson MS; Corper AL; Schiefner A; Havran WL; Wilson IA
Structure; 2011 Jan; 19(1):80-9. PubMed ID: 21220118
[TBL] [Abstract][Full Text] [Related]
17. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
18. CXCR6 is required for antitumor efficacy of intratumoral CD8
Wang B; Wang Y; Sun X; Deng G; Huang W; Wu X; Gu Y; Tian Z; Fan Z; Xu Q; Chen H; Sun Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462326
[TBL] [Abstract][Full Text] [Related]
19. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
[TBL] [Abstract][Full Text] [Related]
20. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]